Company news
4D Molecular Therapeutics, Inc. news in 2022
4D Molecular Therapeutics, Inc.'s news releases, calls and decks from 2022, newest first.
4D Molecular Therapeutics Announces Interim Clinical Data from On-going Phase 1/2 Clinical Trial of Intravitreal 4D-150 for Wet Age-Related Macular Degeneration (wet AMD)
November 13, 2022
4D Molecular Therapeutics Interim Clinical Data from the On-going Phase 1/2 Clinical Trial of 4D-150 for Wet AMD to be Released Monday, November 14, 2022
November 9, 2022
4D Molecular Therapeutics Reports Third Quarter 2022 Financial Results
November 8, 2022
4D Molecular Therapeutics Announces Interim Clinical Data from Phase 1/2 Clinical Trial of 4D-710 for Cystic Fibrosis Lung Disease at NACFC 2022
November 2, 2022
4D Molecular Therapeutics Appoints Noriyuki Kasahara, MD, PhD to the Board of Directors and Promotes Fred Kamal, PhD to President and Chief Operating Officer
September 26, 2022
4D Molecular Therapeutics Reports Second Quarter 2022 Financial Results and Provides 4D-310 Program Update
August 10, 2022
4D Molecular Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Updates
May 11, 2022
4D Molecular Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of 4D-710, an A101 AAV Vector-based, Aerosol-delivered Genetic Medicine for the Treatment of Cystic Fibrosis
April 3, 2022
4D Molecular Therapeutics Reports Full Year 2021 Financial Results and Operational Highlights
March 27, 2022
4D Molecular Therapeutics Announces Resignation of Professor David Schaffer, Ph.D. from the Company’s Board of Directors
February 21, 2022
4D Molecular Therapeutics Announces Updated Interim Results from the 4D-310 Phase 1/2 Clinical Trial in Patients with Fabry Disease at the 18th Annual WORLDSymposium
February 8, 2022
4D Molecular Therapeutics Announces FDA Fast Track Designation Granted to 4D-125 for the Treatment of X-linked Retinitis Pigmentosa
January 9, 2022
4D Molecular Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of 4D-150, a Dual-Transgene Intravitreal Gene Therapy for Patients with wet AMD
January 5, 2022
Decks in 2022
- Investor Presentation (January 2022)
Investor deck · 35 slides · Jan 11, 2022